Shots:
- METiS TechBio has granted Boulevard worldwide development, manufacturing, and commercialization rights to MTS-128, a trispecific T-cell engager (TCE) program
- As per the deal, METiS TechBio will receive a $20M upfront payment & ~$1.6B in development, regulatory, & commercial milestone payments, in addition to tiered royalties on product sales
- MTS-128 is a trispecific T-cell engager designed end-to-end using METiS TechBio’s NanoForge AI-driven molecular engineering platform, showcasing its AI-enabled therapeutic discovery approach
Ref: PRnewswire | Image: METiS TechBio & Boulevard |Press Release
Related News: LENZ Therapeutics Partners with Arrotex Pharmaceuticals to Commercialize Vizz in Australia and New Zealand
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
